EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PAC1 receptor agonist maxadilan alleviates corneal inflammation in a murine model of LPS-induced ocular inflammation

Andras Dobos, Balazs Meresz iD, Inez Bosnyak, Dorottya Molitor, Bela Kocsis, Edina Szabo, Dora Reglodi, Ildiko Vajda, Tamas Atlasz iD, Alexandra Vaczy

PLOS One · 20.07.2026 · 21 (7) · e0353866

DOI: 10.1371/journal.pone.0353866 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 20.07.2026. Verfasst von Andras Dobos und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy, HUN-REN-PTE PACAP Research Team, Centre for Neuroscience, University of Pecs Medical School, Pecs, Hungary. Hauptthemen laut MEDLINE: Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I, Inflammation, Keratitis. Die Arbeit nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research, Development and Innovation Fund, National Brain Research Program, Tématerületi Kiválósági Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ocular inflammation is a leading cause of visual impairment and blindness worldwide. Systemic bacterial infections can spread hematogenously, resulting in endogenous endophthalmitis. These infections present significant diagnostic and therapeutic challenges due to their systemic origin and involvement of multiple ocular structures such as the retina and cornea. Pituitary adenylate cyclase-activating polypeptide (PACAP), acting through its selective receptor PAC1, exerts potent anti-inflammatory, anti-edema, and regenerative effects in various ocular conditions. This study aimed to assess the protective role of maxadilan, a selective PAC1 receptor agonist, in reducing corneal inflammation in a mouse model of lipopolysaccharide (LPS) -induced ocular inflammation. Mice received systemic LPS injections followed by intravitreal administration of maxadilan. Animals were monitored in vivo using optical coherence tomography (OCT) and tonometry. Post-mortem analyses included evaluation of cytokine expression profiles and routine corneal histological assessment. OCT revealed significantly reduced corneal edema and improved tissue structure with maxadilan administration. Additionally, maxadilan lowered intraocular pressure and reduced inflammatory cell infiltration into the aqueous humor. Cytokine profiling showed decreased expression of critical pro-inflammatory mediators such as GM-CSF, IL-6, MIP-1a, TNF-a, and TREM-1 in the maxadilan-treated group. Histological analyses confirmed that maxadilan preserved normal corneal architecture and effectively prevented pathological keratinization compared to untreated controls. These findings suggest that PAC1 receptor activation has therapeutic potential for controlling inflammation and maintaining corneal health in ocular inflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type IInflammationKeratitisAnimalsLipopolysaccharidesMiceDisease Models, AnimalCytokinesMaleCorneaTomography, Optical CoherenceInsect Proteins

Substanzen

LipopolysaccharidesReceptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type Imaxadilan protein, insectCytokinesInsect Proteins

Autor:innen und Institutionen

  • Department of Anatomy, HUN-REN-PTE PACAP Research Team, Centre for Neuroscience, University of Pecs Medical School, Pecs, Hungary.
  • Kiseri Veterinary and Laser Ophthalmology Clinic, Szentes, Hungary.
  • Department of Medical Microbiology and Immunology, University of Pecs, Medical School, Pecs, Hungary.
  • Institute of Physical Education and Sports Science, University of Nyiregyhaza, Nyíregyhaza, Hungary.
  • Department of Sports Biology and Kinesiology; University of Pecs, Pecs, Hungary.

ORCID-Profile: Balazs Meresz, Tamas Atlasz

Förderung

  • National Research, Development and Innovation Fund
  • National Brain Research Program
  • Tématerületi Kiválósági Program

Zitieren

APA

Dobos, A., Meresz, B., Bosnyak, I., Molitor, D., Kocsis, B., Szabo, E., Reglodi, D., Vajda, I., Atlasz, T., & Vaczy, A. (2026). PAC1 receptor agonist maxadilan alleviates corneal inflammation in a murine model of LPS-induced ocular inflammation. PLOS One, 21(7), e0353866. https://doi.org/10.1371/journal.pone.0353866

Vancouver

Dobos A, Meresz B, Bosnyak I, Molitor D, Kocsis B, Szabo E, et al. PAC1 receptor agonist maxadilan alleviates corneal inflammation in a murine model of LPS-induced ocular inflammation. PLOS One. 2026;21(7):e0353866. doi:10.1371/journal.pone.0353866

BibTeX
@article{Dobos2026,
  author = {Dobos, Andras and Meresz, Balazs and Bosnyak, Inez and Molitor, Dorottya and Kocsis, Bela and Szabo, Edina and Reglodi, Dora and Vajda, Ildiko and Atlasz, Tamas and Vaczy, Alexandra},
  title = {PAC1 receptor agonist maxadilan alleviates corneal inflammation in a murine model of LPS-induced ocular inflammation},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {7},
  pages = {e0353866},
  doi = {10.1371/journal.pone.0353866}
}
Kostenlos starten →